Drug reference
moxidectin
Anthelmintic
Anthelmintic
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
C
FDA category + note
Mechanism
Moxidectin, similar to ivermectin, activates ligand-gated Cl- channels, particularly GABA-gated Cl- channels, leading to tonic paralysis of the musculature. It shows a different binding activity for GABA-gated Cl- channels compared to ivermectin and is a poor substrate for P-glycoproteins.
Indications
onchocerciasis due to O. volvulustrichuriasis (when given with albendazole)strongyloidiasisscabies
Dosing
- Adult
- Single dose of 8 mg (four tablets, each containing 2 mg of moxidectin).
Pharmacokinetics
Peak effect
Peak plasma concentrations occur 2 to 6 h after dosing.
Half-life
23.3 days (mean elimination half-life)
Protein binding
Administration with food resulted in an increase of over 30% in Cmax and AUC.
Metabolism
Several hydroxy and oxidative metabolites have been identified in vitro, but levels are low in animals.
Side effects
Common
pruritusrashincreased pulse ratedecreased mean arterial pressurefeverheadachemyalgias
Serious
- Mazzotti reactions
- orthostatic hypotension
- elevated transaminases
Pregnancy & lactation
Pregnancy
C
Lactation
Observed in the breast milk of lactating women.
Related guidelines
Other Unclassified drugs
Ask House about moxidectin
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Goodman & Gilman 14e, Harrison 22e·Updated: 2026-05-10